|
Mutation Information
|
Mutation Site
|
V173L |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.M204V+rt.L180M+rt.V173L |
|
Relevant Drug
|
lamivudine (LAM) |
|
Country
|
Côte d'Ivoire |
Literature Information
|
PubMed PMID
|
25852125
|
|
Disease
|
HBV-HIV coinfection
|
|
Published Year
|
2015 |
|
Journal
|
Antiviral therapy |
|
Title
|
Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire. |
|
Author
|
Boyd A,Moh R,Gabillard D,le Carrou J,Danel C,Anglaret X,Eholié SP,Maylin S,Delaugerre C,Zoulim F,Girard PM,Lacombe K,ANRS 12240 VarBVA study. |
|
Evidence
|
No baseline antiviral resistance mutations were observed. Among 28/127 (22.1%) patients with low-level persistent viraemia (last HBV VL: between 12 to <10(5) copies/ml), no incident amino acid changes associated with antiviral resistance were observed. Among 11/127 (8.7%) patients with high-level persistent viraemia (last HBV VL: >=10(5) copies/ml), only two harboured incident LAM-resistance mutations at positions rtV173L+rtL180M+rtM204V with no patient exhibiting TDF/FTC-resistance.
|
|
|
HBV Mutation Detail Information